BFM
UTHR icon

Boothbay Fund Management’s United Therapeutics UTHR Stock Holding History

Boothbay Fund Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.8M Buy
+75,600
New +$37.7M 0.58% 11
2025
Q4 		– Sell
-800
Closed -$335K – 2392
2025
Q3 		$335K Buy
+800
New +$269K ﹤0.01% 1384
2022
Q2 		– Sell
-11,900
Closed -$2.13M – 2693
2022
Q1 		$2.13M Buy
+11,900
New +$2.27M 0.05% 559
2021
Q2 		– Sell
-120
Closed -$2.01M – 2129
2021
Q1 		$2.01M Buy
120
+41
+52% +$6.84K 0.08% 322
2020
Q4 		$1.2M Buy
+79
New +$10.4K 0.04% 435

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Boothbay Fund Management's UTHR Position: Q4 2025 in Review

Boothbay Fund Management sold out of United Therapeutics (UTHR) in Q4 2025, closing a stake of 3,000 shares — an estimated $1.26M sold.

Boothbay Fund Management first reported a position in UTHR in Q1 2017 and held it in 8 quarters. The position peaked at $1.58M in Q1 2021. 837 funds tracked by Wall St. Rank hold UTHR as of Q4 2025.

  • Boothbay Fund Management reported no remaining United Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 3,000 United Therapeutics shares in Q4 2025, an estimated $1.26M.
  • Boothbay Fund Management first reported a position in United Therapeutics in Q1 2017 and held it in 8 quarters.
  • Boothbay Fund Management's United Therapeutics position peaked at $1.58M in Q1 2021.
  • 837 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.